HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Simoons, M. L. Search for Related Content PubMed PubMed Citation Articles by Simoons, M. L.

A dose-finding study of fondaparinux in patients with non–ST-segment elevation acute coronary syndromes

The Pentasaccharide in Unstable Angina (PENTUA) study

Maarten L. Simoons, MD, FESC, FACC^*,*, Inge W. G. Bobbink, MS, Jean Boland, MD, Martin Gardien, MD^*, Peter Klootwijk, MD^*, Anthonie W. A. Lensing, MD, Witold Ruzyllo, MD, FESC, FACC^||, Victor A. W. M. Umans, MD^¶, Alec Vahanian, MD, FESC, FACC^#, Frans Van De Werf, MD, FESC, FACC^**, Uwe Zeymer, MD, FESC, FACC PENTUA Investigators

^* Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
Organon, Oss, The Netherlands
CHR Citadelle, Luik, Belgium
Academic Medical Center, Amsterdam, The Netherlands
^|| Instytut Kardiologii, Warszawa, Poland
^¶ Medisch Centrum, Alkmaar, The Netherlands
^# Hopital Bichat, Paris, France
^** University Hospital Gasthuisberg, Leuven, Belgium
Städtischen Kliniken, Kassel, Germany

View larger version (29K): [in a new window]   Figure 1 Primary end point: death, myocardial infarction, and recurrent ischemia within nine days in patients treated with fondaparinux or enoxaparin (enox) for the intention-to-treat (upper panel) and per-protocol analyses (lower panel). The shaded area of each bar represents the proportion of patients with death or myocardial infarction. Significant differences were only apparent in the per-protocol analysis, as indicated in the figure.

View larger version (16K): [in a new window]   Figure 2 First occurrence of an event (death, myocardial infarction, or recurrent ischemia) until 30 days in the five treatment groups (intention-to-treat analysis).